About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals dominates the cystic fibrosis market and is expanding into pain therapeutics. Low beta, defensive biotech profile. No dividend. CSP premiums are modest but steady; strike selection is straightforward due to low volatility, though pipeline catalysts can create occasional premium spikes.
Biotechnology